Literature DB >> 24936237

The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing.

Hank F Kung1.   

Abstract

Entities:  

Year:  2012        PMID： 24936237      PMCID： PMC4056942          DOI： 10.1021/ml300058m

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.

Authors:  Hank F Kung; Seok Rye Choi; Wenchao Qu; Wei Zhang; Daniel Skovronsky
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

3.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

Authors:  Henryk Barthel; Hermann-Josef Gertz; Stefan Dresel; Oliver Peters; Peter Bartenstein; Katharina Buerger; Florian Hiemeyer; Sabine M Wittemer-Rump; John Seibyl; Cornelia Reininger; Osama Sabri
Journal:  Lancet Neurol       Date:  2011-04-08       Impact factor: 44.182

4.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 5.  Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Ann Neurol       Date:  2011-10       Impact factor: 10.422

6.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272
  6 in total
  20 in total

1.  Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors.

Authors:  Tamás Kálai; Robin Altman; Izumi Maezawa; Mária Balog; Christophe Morisseau; Jitka Petrlova; Bruce D Hammock; Lee-Way Jin; James R Trudell; John C Voss; Kálmán Hideg
Journal:  Eur J Med Chem       Date:  2014-03-12       Impact factor: 6.514

Review 2.  PET/SPECT imaging agents for neurodegenerative diseases.

Authors:  Lin Zhu; Karl Ploessl; Hank F Kung
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

3.  A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases.

Authors:  Matteo Staderini; Suzana Aulić; Manuela Bartolini; Hoang Ngoc Ai Tran; Víctor González-Ruiz; Daniel I Pérez; Nieves Cabezas; Ana Martínez; M Antonia Martín; Vincenza Andrisano; Giuseppe Legname; J Carlos Menéndez; Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2012-12-28       Impact factor: 4.345

4.  "It Ain't Over 'til It's Over" (a) -The Search for Treatments and Cures for Alzheimer's Disease.

Authors:  Richard J Hargreaves
Journal:  ACS Med Chem Lett       Date:  2012-10-29       Impact factor: 4.345

5.  Cyclopropyl-Fused 1,3-Thiazepines as BACE1 and BACE2 Inhibitors.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2013-03-15       Impact factor: 4.345

Review 6.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

7.  Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease.

Authors:  Xianhai Huang; Wei Zhou; Xiaoxiang Liu; Hongmei Li; George Sun; Mihirbaran Mandal; Monica Vicarel; Xiaohong Zhu; Chad Bennett; Troy McCraken; Dmitri Pissarnitski; Zhiqiang Zhao; David Cole; Gioconda Gallo; Zhaoning Zhu; Anandan Palani; Robert Aslanian; John Clader; Michael Czarniecki; William Greenlee; Duane Burnett; Mary Cohen-Williams; Lynn Hyde; Lixin Song; Lili Zhang; Inhou Chu; Alexei Buevich
Journal:  ACS Med Chem Lett       Date:  2012-09-04       Impact factor: 4.345

8.  5-Amino-oxazepine and 5-Amino-thiazepine Compounds as β-Secretase Antagonists and Methods of Use: Patent Highlight.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2012-10-29       Impact factor: 4.345

Review 9.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

10.  The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy.

Authors:  Angela Smilansky; Liron Dangoor; Itay Nakdimon; Danya Ben-Hail; Dario Mizrachi; Varda Shoshan-Barmatz
Journal:  J Biol Chem       Date:  2015-11-05       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.